Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

16090MCLA-158-CL01-NCT03526835OpenPhase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid TumorsMCLA-158-CL01NCT03526835IndustrialAdultTreatmentI/IINationalOtherWeinberg, BenjaminGeorgetown University Medical Center : Susan Lawrence; Lombardi Comprehensive Cancer Center : Susan LawrenceGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS17105Susan LawrenceSusan Lawrencesl2328@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>